AD_____

GRANT NUMBER DAMD17-94-J-4398

TITLE: Targeted Gene Delivery to Accomplish Gene Therapy for Breast Cancer

PRINCIPAL INVESTIGATOR: David T. Curiel, M.D.

CONTRACTING ORGANIZATION: University of Alabama at Birmingham
Birmingham, Alabama 35294

REPORT DATE: August 1998

TYPE OF REPORT: Final

PREPARED FOR: Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, Maryland 21702-5012

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE	3. REPORT TYPE AND DATES COVERED
	August 1998	Final (1 Aug 94 - 31 Jul 98)

4. TITLE AND SUBTITLE
Targeted Gene Delivery to Accomplish Gene Therapy for Breast Cancer

5. FUNDING NUMBERS
DAMD17-94-J-4398

6. AUTHOR(S)
David T. Curiel, M.D.

7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES)
University of Alabama at Birmingham
Birmingham, Alabama 35294

8. PERFORMING ORGANIZATION REPORT NUMBER

9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)
Commander
U.S. Army Medical Research and Materiel Command
Fort Detrick, Frederick, MD 21702-5012

10. SPONSORING/MONITORING AGENCY REPORT NUMBER

11. SUPPLEMENTARY NOTES

12a. DISTRIBUTION / AVAILABILITY STATEMENT
Approved for public release; distribution unlimited

12b. DISTRIBUTION CODE

13. ABSTRACT *(Maximum 200*

We are developing methods to derive gene transfer vectors capable of accomplishing targeted gene delivery to metastatic breast cancer cells. In this regard, strategies have been explored to modify adenoviral vectors by altering their binding tropism. Genetic methods employed have allowed for the modification of the native adenoviral binding protein (fiber) to incorporate cancer-relevant cell-binding ligands. Immunologic methods have yielded an antifiber antibody which specifically ablates native adenoviral tropism and provides a site for the addition of breast cancer-relevant ligands. The results developed herein have allowed for the successful retargeting of the adenoviral vector via either the genetic or immunologic approach. In addition, targeted, tumor-specific gene delivery has been achieved *in vitro*. These methods will now allow the evaluation of these vector systems in *in vivo* models of human breast cancer. The utility of the vectors in this context will allow the development of gene therapy strategies for disseminated breast cancer.

14. SUBJECT TERMS	15. NUMBER OF PAGES
Gene Therapy, Vector, Molecular Conjugate, Metastatic Disease, Gene Transfer, Molecular Chemotherapy, Breast Cancer	11
	16. PRICE CODE

17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT
Unclassified	Unclassified	Unclassified	Unlimited

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

N/A Where copyrighted material is quoted, permission has been obtained to use such material.

N/A Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

N/A Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

N/A For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

X In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

X In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

___ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

PI - Signature 7/23/91 Date

TABLE OF CONTENTS

DEPARTMENT OF THE ARMY

FINAL – ANNUAL REPORT

GRANT NUMBER: DAMD 17-94-J-4398

David T. Curiel, M.D.

In the initial phases of this research, we developed methods to re-target adenovirus to achieve cell-specific gene delivery to breast cancer tumor cells. In this regard, both immunologic and genetic approaches were studied with respect to achieving tropism-modification of adenoviral vectors. In addition, we addressed the means to achieve long term gene expression via adenoviral vectors. In this final year of funding, we tested these vector systems for gene delivery efficacy in stringent *in vivo* models.

In the immunologic approach, we successfully re-routed the adenovirus via heterologous cellular pathways. Specifically, the virus could be delivered via over-expressed growth factor receptors relevant to breast cancer, including folate, Epidermal Growth Factor and Fibroblast Growth Factor. As a final proof-of-principle, for *in vivo* utility, we employed the immunologically re-targeted adenovirus in a model of malignant ascites. In this model, an fibroblast growth factor-retargeted adenovirus could enhance delivery to tumor cells in situ. Of note in this regard, retargeted adenovirus employed to delivery a toxin gene Herpes Simplex Virus Thymidine Kinase, could enhance survival in this model as compared to non-retargeted virus. Thus, for this breast cancer relevant to disease complication, immunologic re-targeting allowed enhanced tumor transduction which translated into valid survival advantage.

We next tested whether the immunologic approach could maintain targeting fidelity in the context of systemic administration. Specifically, a major problem with systemically administered adenovirus vectors is hepatic uptake and sequestration. Thus, "un-targeting" the liver is a key goal in adenovirus tropism-modification schemas. In these experiments, an Fibroblast growth factor retargeted adenovirus exhibited dramatically reduced hepatic uptake to the liver compared to un-retargeted adenovirus. Of note, this liver "un-targeting" also achieved reduced vector related toxicity and immunogenicity. Thus, it is clear that such tropism modification can indeed allow reduction in non-specific vector-mediated gene delivery. Further, this phenomenon may accrue additional benefits with respect to the overall vector therapeutic index profile.

We also developed an immunologic approach for tumor re-targeting based on modification of the adenovirus capsid proteins. To this end, we demonstrated that heterologous peptides could be inserted into the HI loop of the fiber knob without perturbation of the virus propagation/infection dynamics. To demonstrate the targeting utility of this locale, an RGDC peptide was configured into the HI loop. This peptide, defined by *in vivo* phage panning techniques, possesses affinity for integrins of the $\alpha_V \beta_3$ and $\alpha_V \beta_5$ class. Of note, dysregulation of these integrins is associated with various neoplasms, including carcinoma of the breast, producing a viable targeting axis.

The RGD modified adenovirus (AdRGD) was then employed for transduction of various "adenovirus-refractory" cells. Initially, HUVEC were employed, as these cells are deficient in the 1° adenovirus receptor, CAR. This system thus produces a convenient assay of the ability of the tropism-modified adenovirus to achieve "Coxsackie-Adenovirus Receptor-independent gene transfer", an essential requirement of targeting strategies. In these studies, the AdRGD augmented gene delivery to these cells by two orders of magnitude compared to un-modified adenovirus. Of note, blocking experiments with recombinant knob demonstrated that this augmentation was based on CAR-independent gene transfer. Thus, the HI loop proved to be a propitious locale for localizing re-targeting motifs.

The AdRGD was next employed to transduce fresh primary carcinoma cells. Of note, our studies, and those of others, have revealed coxsackie-adenovirus receptor deficiency as a highly prevalent feature of tumor cells. Indeed, this aspect of tumor biology is an essential factor in the poor rates of tumor transduction noted in human clinical trials. In these studies, the AdRGD achieved dramatic augmentations of gene delivery to fresh primary tumor cells. Specifically, augmentations of between 3-4 orders of magnitude were noted in gene transfer efficiency. As before, the basis of this augmentation was the coxsackie-adenovirus receptor-independence of the delivery schema. Thus, in this substrate with highest relevance to human tumor, our re-targeted adenovirus exhibited a substantially enhanced gene delivery efficacy compared to un-modified adenovirus.

We next tested the fidelity of this genetic re-targeting schema *in vivo*. Of note in this regard, genetic re-targeting schemas reported by others, based on fiber carboxy (COOH terminus) modifications, do not maintain re-targeting efficacy in the systemic circuit. It was thus key to determine the merit of the HI loop locale in this context. Comparison of gene delivery distribution was then endeavored for AdRGD vs. un-modified adenovirus after systemic delivery. In these studies, the AdRGD exhibited a distinctly different profile of reporter gene distribution compared to the control. Specifically, greatly enhanced uptake was noted in organs where the vessel beds were characterized by $\alpha_V \beta_3$ and $\alpha_V \beta_5$ integrins. Thus, targeting *in vivo* had been achieved via HI loop modifications of adenovirus.

We are presently engaged in employing the AdRGD vector to deliver therapeutic genes in murine models of carcinoma of the breast. The present line of investigation has made feasible the proposal of targeting metastatic disease via systemically administered vectors. Efficacy in these studies will provide the rationale for human clinical trials on this basis. In this regard, Department of Defense support provided the means for us to establish these new vector paradigms. We believe that the vectors we have derived will have important relevance for carcinoma of the breast gene therapy strategies. In addition, these

vector developments will likely have implications for all gene therapy approaches based on *in vivo* delivery via adenovirus vectors.

List of Publications/Meeting Abstracts

Krasynkh VN, Mikheeva GV, Douglas JT, and **Curiel DT**. Generation of recombinant adenoviral vectors with modified fibers for altering viral tropism. Journal of Virology 70:6839-6846, 1996.

Douglas JT, Rogers BE, Rosenfeld ME, Michael SI, Feng M, and **Curiel DT**. Targeted gene delivery by tropism-modified adenoviral vectors. Nature Biotech 14:1574-1578, 1996.

Goldman C, Soroceanu L, Smith N, Gillespie GY, Shaw W, Burgess S, Bilbao G, and **Curiel DT**. *In vitro* and *in vivo* gene delivery mediated by a synthetic polycationic amino polymer. Nature Biotech 15:462-466, 1997.

Rogers BE, **Curiel DT**, Khazaeli MB, Grizzle WF, Laffoon K, McLean S, and Buchsbaum DJ. Radiolabeled ligand binding to cells induced to express the epidermal growth factor receptor using a recombinant adenoviral vector. J Nucl Med 38:18P, 1997.

Goldman CK, Rogers BE, Douglas JT, Sosnowski BA, Siegal GP, Campain JA, and **Curiel DT**. Targeted gene delivery to Kaposi's sarcoma cells via the fibroblast growth factor receptor. Cancer Res 57(8):1447-1451, 1997.

Hong SS, Karayan L, Tournier J, **Curiel DT**, and Boulanger PA. Adenovirus type 5 fiber knob binds to MHC class 1*a*2 domain at the surface of human epithelial and B lymphoplastoid cells. EMBO J 9:2294-2306, 1997.

Bilbao G, Feng M, Rancourt C, Jackson Jr, W., and **Curiel DT**. Adenoviral/retroviral vector chimeras: a novel strategy to achieve high efficiency stable transduction *in vivo*. FASEB J 11(8):624-634, 1997.

Feng M, Jackson Jr. WH, Goldman CK, Rancourt C, Wang M, and **Curiel DT**. Stable *in vivo* transduction via a novel adenoviral/retroviral chimeric vector. Nature Biotech 15:866-870, 1997.

Rogers BE, Douglas JT, Ahlem C, Sosnowski BA, Frincke J, and **Curiel DT**. Use of a novel cross-linking method to achieve tropism-modification of adenoviral vectors. Gene Ther 4:1387-1392, 1997.

Krasnykh V, Dmitriev I, Mikheeva G, Belousova N, and **Curiel DT**. Characterization of an adenoviral vector containing a heterologous peptide epitope in the HI-Loop of the fiber knob. J Virol 72(3):1844-1852, 1998.

Campain JA, Matassa AA, Felgner PL, Barnhart KM, **Curiel DT**, and Harrison GS. Lipid- and adenoviral-mediated gene transfer into AIDS-KS cell lines. Cancer Gene Therapy 5(3):131-143, 1998.

Zhang HG, Bilbao G, Zhou T, Contreras JL, Gomez-Navarro J, Feng M, Saito I, Mountz JD, **Curiel DT**. Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression. J Virol 72(3):2483-2490, 1998.

Reynolds PN, Miller CR, Goldman CK, Douglas J, Sosnowski BA, Rogers BE, Gomez-Navarro J, Pierce GF, **Curiel DT**, Douglas JT. Targeting adenoviral infection via fibroblast growth factor receptors enhances gene delivery to vascular endothelial and smooth muscle cells. (Submitted).

Reviews and Chapters

Grushcow J, and **Curiel DT**. Gene therapy for carcinoma of the breast. Cancer Gene Ther 4:195-202, 1995.

Douglas J, and **Curiel DT**. Targeted gene therapy. Tumor Targeting 1:67-84, 1995.

Cristiano RD, and **Curiel DT**. Strategies to accomplish gene delivery via the receptor mediated endocytosis pathway. Cancer Gene Ther 121:19-23, 1995.

Curiel DT. Gene therapy approaches for treatment of cancer. Cecil Textbook of Medicine, 20th Ed, Chapter VI-C; Dr. J. Claude Bennett, M.D., Fred Plumb, M.D., editors; W.B. Saunders Company, pages 98-117, 1996.

Rosenfeld ME, and **Curiel DT**. Gene therapy strategies for novel cancer therapeutics. Current Opinion in Oncology 8:72-77, 1996.

Curiel DT. Vectors for cancer Gene Therapy. Science and Medicine 3:10-11, 1996.

Bilbao G, and **Curiel DT**. Gene therapy for cancer therapeutics. Oncologic, Endocrine & Metabolic. Ashley Publications 3:1267-1284, 1997.

Douglas JT, and **Curiel DT**. Adenoviruses as vectors for gene therapy. Science and Medicine 4:44-53, 1997.

Douglas JT, and **Curiel DT**. Targeted adenoviral vectors for cancer gene therapy. Int J Oncology 11:341-348, 1997.

Bilbao G, Gomez-Navarro J, and **Curiel DT**. Advances in adenoviral vectors for cancer gene therapy. Expert Opinion on Therapeutic Patents. 7(12):1427-1446, 1997.

Feng M, and **Curiel DT**. Adenoviral-retroviral chimeras: the best of both worlds? (Submitted).

List of Personnel

David T. Curiel, M.D.

Joanne T. Douglas, Ph.D.

Galina Mikheeva

Myung Kim